Aardvark Reports Wider FY25 Net Loss, Expects Q2 2026 Update on Paused ARD-101 Trial

Aardvark Therapeutics reported a wider net loss of $57.59 million for FY25, compared to $20.59 million in the prior year. The company's lead compound, ARD-101, is in Phase 3 clinical development for Prader-Willi Syndrome, but its development has been paused due to unexpected reversible cardiac observations in a separate trial. Aardvark expects to update on the trial in Q2 2026 and has also voluntarily paused the ARD-201 trials. The firm has sufficient funds to support operations into Q2 2027.